Akebia Therapeutics (AKBA) Earnings Dates, Call Summary & Reports

Compare

1,617 Followers

Earnings Data

Report Date

May 11, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.03

Last Year’s EPS

0.03

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 26, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed substantive progress: a successful commercial launch of Vafseo with meaningful early prescriber traction and access, significant year-over-year revenue growth (~47%) and a materially improved balance sheet (cash up to $184.8M), supported by promising clinical and cost data that could drive longer-term adoption. Offsetting these positives were slower adoption in H2 2025, a one-time $4.8M inventory drawdown related to an in-center dosing transition, rising R&D spend (including a $12.8M acquired R&D charge) and expected 2026 pressure on Auryxia from generics. Overall the positives (revenue growth, cash position, clinical evidence, expanding prescriber/access and pipeline catalysts) outweigh the near-term operational and competitive headwinds.

Company Guidance

Management did not give revenue guidance but provided numerous metric-based signposts: Vafseo demand was about $11M in Q4 (Q4 net product revenue $6.2M; calendar 2025 Vafseo net $45.8M), with demand roughly flat to ~$12M in Q2–Q3; a one‑time USRC inventory drawdown of ~$4.8M impacted Q4. Total 2025 net product revenue for Vafseo + Auryxia was $227M (Auryxia: $48.1M Q4, $181.5M CY), total revenues were $236.2M for 2025 ($57.6M Q4), Q4 COGS $12.5M, Q4 R&D $26.6M, Q4 SG&A $26.1M, Q4 net loss $12.2M and FY net loss $5.3M. Commercial and operational metrics: >1,000 prescribers across 24 dialysis organizations, ~800 prescribers wrote scripts in Q4 (average ~10.3 prescriptions; 128 new prescribers), 290,000 patients now have clinic access, ~25% of Q4 new patients were outside USRC, and management expects the vast majority of USRC in‑center patients to be on 3x/week observed dosing by end of Q1. Adherence improved (first‑refill rates rose from ~75% to ~91% in the observed‑dosing subset in Q4; ~87% in January in the larger observed cohort) and providers continue protocol rollouts. Financial runway and pipeline guidance: cash was $184.8M as of 12/31/25 (vs $51.9M a year earlier) and is expected to fund operations for at least two years; Auryxia revenue is expected to decline in 2026 due to expanding generics; VOCAL topline is expected late 2026 and VOICE in early 2027; praliciguat Phase II plans to enroll ~60 patients with a 24‑week UPCR endpoint, AKB‑097 Phase II basket to start H2 2026 (initial data 2027), and AKB‑9090 Phase I in H1 2026 with topline later in the year. Management also highlighted health‑economic INNO2VATE findings: 7.7% lower annual hospitalization rate, 16% fewer hospitalization days, ~15% lower Medicare hospitalization costs, ~$3,700 saved per patient per year (~$2B annual if all eligible patients treated).

Strong Full-Year Revenue Growth

Total revenues increased to $236.2M in 2025 from $160.2M in 2024, a ~47% year-over-year increase driven by the U.S. introduction of Vafseo and higher Auryxia sales.

Net Product Revenue and Launch Traction

Vafseo and Auryxia combined generated $227M in net product revenue in 2025. Vafseo net product revenue totaled $45.8M for the year ($6.2M in Q4) following commercial launch.

Growing Prescriber Base and Clinic Access

More than 1,000 prescribers across 24 dialysis organizations have written prescriptions for Vafseo; ~290,000 patients have access in dialysis clinics with protocols in place. In Q4 ~800 prescribers wrote scripts (128 were new), averaging ~10.3 prescriptions per prescriber.

Improving Adherence Metrics

First-refill adherence improved from ~75% (earlier 2025) to ~91% among the observed-dosing subset in Q4, with January early-Q1 data showing ~87% first-refill adherence in a larger observed-dosing population and sustained high 80s–90s adherence into subsequent refills.

Clinical Evidence Supporting Benefits and Cost Savings

Post-hoc INNO2VATE analysis showed lower risk of death/hospitalization vs ESA; cost comparison presented shows 7.7% lower annual hospitalization rate, 16% fewer hospitalization days and ~15% lower Medicare hospitalization costs with Vafseo, implying ~$3,700 per patient-year savings (nearly $2B/year if broadly adopted).

Material Balance Sheet Improvement

Cash and cash equivalents increased to $184.8M as of Dec 31, 2025 from $51.9M a year earlier, an increase of ~$133M, and management expects existing cash and operations to fund plans for at least two years.

Pipeline Progress and Near-Term Catalysts

Multiple clinical and pipeline milestones planned: VOCAL topline (Vafseo 3x weekly) expected late 2026, VOICE data expected early 2027, AKB-097 Phase II basket trial initiation in H2 2026 (initial data 2027), praliciguat FSGS Phase II enrolling, and AKB-9090 Phase I initiation in H1 2026 with topline later in 2026.

Improved Profitability Trends

Net loss narrowed materially to $5.3M for calendar year 2025 from $69.4M in 2024. Q4 net loss improved to $12.2M from $22.8M a year earlier, reflecting higher product revenue partially offset by investment spending.

Akebia Therapeutics (AKBA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AKBA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 11, 2026	2026 (Q1)	-0.03 / -	0.03	―	―	―
Feb 26, 2026	2025 (Q4)	-0.04 / -0.05	-0.1	50.00% (+0.05)	―
Nov 10, 2025	2025 (Q3)	-0.01 / 0.00	-0.1	―	―
Aug 07, 2025	2025 (Q2)	-0.01 / 0.00	-0.04	―	―
May 08, 2025	2025 (Q1)	-0.04 / 0.03	-0.09	133.33% (+0.12)	―
Mar 13, 2025	2024 (Q4)	-0.08 / -0.10	0	―	―
Nov 07, 2024	2024 (Q3)	-0.06 / -0.10	-0.08	-25.00% (-0.02)	―
Aug 08, 2024	2024 (Q2)	-0.07 / -0.04	-0.06	33.33% (+0.02)	―
May 09, 2024	2024 (Q1)	-0.07 / -0.09	-0.14	35.71% (+0.05)	―
Mar 14, 2024	2023 (Q4)	-0.04 / 0.00	-0.04	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AKBA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 26, 2026	$1.21	$1.32	+9.09%
Nov 10, 2025	$2.04	$1.67	-18.14%
Aug 07, 2025	$3.79	$3.01	-20.48%
May 08, 2025	$2.46	$2.62	+6.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Akebia Therapeutics (AKBA) report earnings?

Akebia Therapeutics (AKBA) is schdueled to report earning on May 11, 2026, After Close (Confirmed).

What is Akebia Therapeutics (AKBA) earnings time?

Akebia Therapeutics (AKBA) earnings time is at May 11, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AKBA EPS forecast?

AKBA EPS forecast for the fiscal quarter 2026 (Q1) is -0.03.